On Wednesday, XBIOTECH INC. (NASDAQ:XBIT)’s shares surged 22.37% to $23.25, hitting its highest level.
XBIOTECH, declared recently the pricing of its initial public offering of 4,000,000 shares of its common stock at an initial public offering price of $19.00 per share for a total offering amount of $76,000,000, before the underwriting discount. The shares commenced trading on the NASDAQ Global Select Market on Wednesday, April 15, 2015 under the ticker symbol “XBIT.”
WR Hambrecht + Co is acting as the sole underwriter for the offering.
XBiotech is a leading developer of next-generation therapeutic antibodies. The Company is also innovating with manufacturing technology and clinical strategies to lessen capital requirements and reduce lead times for drug development.
Warren Resources Inc. (NASDAQ:WRES)’s shares gained 21.57% to $1.24, during the last trading session on Wednesday, as oil prices rose for a second day.
WTI crude oil for May delivery was up 4.2% to $55.55 a barrel early Wednesday afternoon, and Brent crude oil for May delivery was up 2.5% to $59.88 a barrel.
The rising oil prices come after the U.S. Energy Information Administration declared that U.S. crude oil inventories grew by 1.3 million barrels to 483.7 million in the week ending April 10, their highest levels in at least 80 years. Analysts surveyed by the Wall Street Journal predictable inventories to raise by 3.6 million last week.
Warren Resources, Inc., an independent energy company, engages in the exploration, development, and production of domestic onshore crude oil and gas reserves. The company primarily focuses on the exploration and development of waterflood oil recovery projects in the Wilmington field within the Los Angeles Basin of California; Marcellus Shale project in northeastern Pennsylvania; and coalbed methane natural gas properties located in the Rocky Mountain region.
At the end of Wednesday’s trade, Celsion Corp. (NASDAQ:CLSN)’s shares gained 18.55% to $3.15.
Celsion Corporation, declared positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in recurrent chest wall (RCW) breast cancer. The trial is designed to enroll up to 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia. Of the 16 patients enrolled and treated, 12 were eligible for evaluation of efficacy. Based on data accessible to date, 67% of patients practiced a clinical benefit of their highly refractory disease with a local response rate of 58% observed in the 12 evaluable patients, notably 5 complete responses (CR), 2 partial responses (PR) and 1 patient with stable disease (SD). The Company remains on track to complete enrollment in the study in the third quarter of 2015.
“The objective tumor response data counting 5 complete responses emerging from the Phase 2 DIGNITY study are extremely impressive, particularly since the patients in the trial presented with highly resistant chest wall tumors that had progressed on multiple therapies, counting chemotherapy, radiation and hormone therapy,” noted Dr. Nicholas Borys, Celsion’s Senior Vice President and Chief Medical Officer. “Together with the data from earlier Phase 1 studies, these interim results highlight the noteworthy potential of ThermoDox® plus hyperthermia to stabilize disease in this difficult-to-treat patient population, and we look forward to bringing this trial to completion later this year.”
Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology.
Finally, Paragon Offshore plc (NYSE:PGN), ended its Wednesday’s trading session with 17.75% gain, and closed at $1.99.
Paragon Offshore, declared that it plans to report financial results for the first quarter 2015 on Wednesday, May 13, 2015, after the close of trading on the New York Stock Exchange. Copies of Paragon’s earnings release will be accessible on its website at www.paragonoffshore.com.
Paragon also has planned a teleconference and webcast related to its first quarter 2015 results on Thursday, May 14, 2015, at 8:00 a.m. U.S. Central Daylight Time. The teleconference can be accessed from the U.S. and Canada by dialing 1-888-771-4371, or internationally by dialing 1-847-585-4405, and using access code: 39310592. Interested parties may also listen to the webcast through a link posted on Paragon’s website at www.paragonoffshore.com, under “Events & Presentations” in the “Investor Relations” section of the website.
A telephonic replay of the conference call will be accessible on Thursday, May 14, 2015, starting at about 12:00 p.m. U.S. Central Daylight Time, through Thursday, May 28, 2015, ending at about 11:00 p.m. U.S. Central Daylight Time.
Paragon Offshore plc, together with its auxiliaries, provides offshore drilling rigs. The company is involved in contracting its rigs, related equipment, and work crews to conduct oil and gas drilling and workover operations for its exploration and production customers on a day rate basis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
